ArticleJournal of cardiothoracic surgery2026
Exclusion of the left atrial appendage in Chinese population with perclip system: 1-year follow-up outcome results from a prospective, multi-center, open-label, single-arm device trial.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
17 authors.
Funding
Abstract
backgroundAtrial fibrillation (AF) significantly increases stroke risk, particularly through left atrial appendage (LAA) involvement. This trial evaluated the safety and efficacy of the Perclip system for LAA exclusion in Chinese AF patients.
methodsThis prospective study recruited patients with AF and CHA
resultsPerclip implantation was performed on 76 participants (concomitantly with open-heart surgery in 65 participants). The device was successfully implanted in all subjects. The complete LAA closure rate was 98.7% (75/76) at 30 days and 100% (75/75) at 3 months post-surgery. The incidence of device-related serious adverse events within 30 days after surgery was 1.3% (1/76). One participant, who underwent left atrial plication and LAA occlusion, developed an atrial thrombus. Additionally, there were no cases of cardiovascular death, cardiac structural damage, myocardial infarction, major bleeding, stroke, or non-central nervous system embolism within 12 months post-surgery.
conclusionsThis 1-year multicenter trial supports the efficacy and safety of the Perclip system for LAA exclusion in Chinese AF patients. Long-term follow-up will provide additional insights into the outcomes of the Perclip system.
trial registrationThis trial was retrospectively registered on the Chinese Clinical Trial Registry ( http://www.chictr.org.cn/ ) on January 31, 2024. REGISTRATION NUMBER: ChiCTR2400080521.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.